Multiple developments in delivery formulations and the chemical structure of the oligonucleotides were made to enhance siRNA efficacy in targeting oncogenic KRAS in lung, colon, and pancreatic cancer cells. The gene discussed is KRAS; the disease is pancreatic neoplasm.